title: Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia.
abstract: BACKGROUND
  Doxycycline has a high degree of activity against many common respiratory pathogens and has been used in the outpatient management of lower respiratory tract infections, including pneumonia.
  
  
  OBJECTIVE
  To evaluate the efficacy of intravenous doxycycline as empirical treatment in hospitalized patients with mild to moderately severe community-acquired pneumonia.
  
  
  METHODS
  We conducted a randomized prospective trial to compare the efficacy of intravenous doxycycline with other routinely used antibiotic regimens in 87 patients admitted with the diagnosis of community-acquired pneumonia. Forty-three patients were randomized to receive 100 mg of doxycycline intravenously every 12 hours while 44 patients received other antibiotic(s) (control group). The 2 patient groups were comparable in their clinical and laboratory profiles.
  
  
  RESULTS
  The mean+/-SD interval between starting an antibiotic and the clinical response was 2.21+/-2.61 days in the doxycycline group compared with 3.84+/-6.39 days in the control group (P = .001). The mean+/-SD length of hospitalization was 4.14+/-3.08 days in the doxycycline group compared with 6.14+/-6.65 days in the control group (P = .04). The median cost of hospitalization was $5126 in the doxycycline group compared with $6528 in the control group (P = .04). The median cost of antibiotic therapy in the doxycycline-treated patients ($33) was significantly lower than in the control group ($170.90) (P<.001). Doxycycline was as efficacious as the other regimens chosen for the treatment of community-acquired pneumonia.
  
  
  CONCLUSIONS
  Doxycycline is an effective and inexpensive therapy for the empirical treatment of hospitalized patients with mild to moderately severe community-acquired pneumonia.
authors.affiliation: Department of Medicine, Meridia Huron Hospital, Cleveland, Ohio 44112, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Ailani
authors.forename: G
authors.initials: G
authors.lastname: Agastya
authors.forename: R K
authors.initials: RK
authors.lastname: Ailani
authors.forename: B N
authors.initials: BN
authors.lastname: Mukunda
authors.forename: R
authors.initials: R
authors.lastname: Shekar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D004318:Doxycycline / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D005260:Female; D006760:Hospitalization; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D012720:Severity of Illness Index; D016896:Treatment Outcome